Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies

The October issue of the American Journal of Clinical Dermatology features an article by several researchers from Curta. The article highlights how ruxolitinib cream treatment for patients with atopic dermatitis affects their work productivity and ability to engage in activities based on a post hoc analysis of pooled data from ruxolitinib phase III studies and quantifies the savings due to productivity gains with ruxolitinib cream treatment vs placebo.

To access the full publication, visit:
https://pubmed.ncbi.nlm.nih.gov/36264430/